Cargando…
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and differentiation. Evidence demonstrating the expression of BT...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005125/ https://www.ncbi.nlm.nih.gov/pubmed/36903645 http://dx.doi.org/10.3390/molecules28052400 |
_version_ | 1784905003074322432 |
---|---|
author | Rozkiewicz, Dariusz Hermanowicz, Justyna Magdalena Kwiatkowska, Iwona Krupa, Anna Pawlak, Dariusz |
author_facet | Rozkiewicz, Dariusz Hermanowicz, Justyna Magdalena Kwiatkowska, Iwona Krupa, Anna Pawlak, Dariusz |
author_sort | Rozkiewicz, Dariusz |
collection | PubMed |
description | In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and differentiation. Evidence demonstrating the expression of BTK on the majority of hematological cells has led to the hypothesis that BTK inhibitors (BTKIs) such as ibrutinib can be an effective treatment for leukemias and lymphomas. However, a growing body of experimental and clinical data has demonstrated the significance of BTK, not just in B-cell malignancies, but also in solid tumors, such as breast, ovarian, colorectal, and prostate cancers. In addition, enhanced BTK activity is correlated with autoimmune disease. This gave rise to the hypothesis that BTK inhibitors can be beneficial in the therapy of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), Sjögren’s syndrome (SS), allergies, and asthma. In this review article, we summarize the most recent findings regarding this kinase as well as the most advanced BTK inhibitors that have been developed to date and their clinical applications mainly in cancer and chronic inflammatory disease patients. |
format | Online Article Text |
id | pubmed-10005125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100051252023-03-11 Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials Rozkiewicz, Dariusz Hermanowicz, Justyna Magdalena Kwiatkowska, Iwona Krupa, Anna Pawlak, Dariusz Molecules Review In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and differentiation. Evidence demonstrating the expression of BTK on the majority of hematological cells has led to the hypothesis that BTK inhibitors (BTKIs) such as ibrutinib can be an effective treatment for leukemias and lymphomas. However, a growing body of experimental and clinical data has demonstrated the significance of BTK, not just in B-cell malignancies, but also in solid tumors, such as breast, ovarian, colorectal, and prostate cancers. In addition, enhanced BTK activity is correlated with autoimmune disease. This gave rise to the hypothesis that BTK inhibitors can be beneficial in the therapy of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), Sjögren’s syndrome (SS), allergies, and asthma. In this review article, we summarize the most recent findings regarding this kinase as well as the most advanced BTK inhibitors that have been developed to date and their clinical applications mainly in cancer and chronic inflammatory disease patients. MDPI 2023-03-06 /pmc/articles/PMC10005125/ /pubmed/36903645 http://dx.doi.org/10.3390/molecules28052400 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rozkiewicz, Dariusz Hermanowicz, Justyna Magdalena Kwiatkowska, Iwona Krupa, Anna Pawlak, Dariusz Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials |
title | Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials |
title_full | Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials |
title_fullStr | Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials |
title_full_unstemmed | Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials |
title_short | Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials |
title_sort | bruton’s tyrosine kinase inhibitors (btkis): review of preclinical studies and evaluation of clinical trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005125/ https://www.ncbi.nlm.nih.gov/pubmed/36903645 http://dx.doi.org/10.3390/molecules28052400 |
work_keys_str_mv | AT rozkiewiczdariusz brutonstyrosinekinaseinhibitorsbtkisreviewofpreclinicalstudiesandevaluationofclinicaltrials AT hermanowiczjustynamagdalena brutonstyrosinekinaseinhibitorsbtkisreviewofpreclinicalstudiesandevaluationofclinicaltrials AT kwiatkowskaiwona brutonstyrosinekinaseinhibitorsbtkisreviewofpreclinicalstudiesandevaluationofclinicaltrials AT krupaanna brutonstyrosinekinaseinhibitorsbtkisreviewofpreclinicalstudiesandevaluationofclinicaltrials AT pawlakdariusz brutonstyrosinekinaseinhibitorsbtkisreviewofpreclinicalstudiesandevaluationofclinicaltrials |